Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZL-1102

Other · developed by Zai Lab

Phase 2 Most advanced trial (none active)
ZLAB Developer
1 Registered trials

What is ZL-1102?

ZL-1102 is a topical gel formulated at 1% and 3% w/w and applied twice or once daily. It is being studied in plaque psoriasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Zai Lab, Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
GF6GE8M3C4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06380907 Phase 2 Plaque Psoriasis Terminated ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plaque Psoriasis

More from Zai Lab

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind ZL-1102

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.